Physician profile
Kathryn M Hebert
NPI 1124346218
$5,769.11
in general payments reported to CMS, 2019-2025
27 companies · $1,292 in 2025
The $1,292 reported for 2025 was more than what 85% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $928 · 2022: $808 · 2023: $1,703 · 2024: $1,037 · 2025: $1,292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,020 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,020.14 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,098.42 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $652.48 | 2021-2025 | Caplyta |
| Alkermes, INC. | $606.16 | 2021-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $575.57 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Otsuka America Pharmaceutical, INC. | $518.49 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $471.19 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $369.98 | 2022-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $223.03 | 2021-2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $202.13 | 2021 | |
| Supernus Pharmaceuticals, INC. | $174.18 | 2023-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $152.99 | 2021-2025 | Ingrezza |
| Corium, LLC | $139.23 | 2023-2025 | Azstarys |
| Axsome Therapeutics, INC. | $111.02 | 2023-2025 | Auvelity |
| Lundbeck LLC | $71.09 | 2021-2024 | Rexulti |
| Noven Therapeutics, LLC | $51.38 | 2023-2024 | Xelstrym, Secuado |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $42.06 | 2024 | Perseris |
| Avanir Pharmaceuticals, INC. | $41.70 | 2021 | |
| Braeburn INC. | $40.53 | 2025 | Brixadi |
| Bausch Health US, LLC | $36.01 | 2023 | Wellbutrin, Aplenzin |
| Neos Therapeutics, LP | $34.87 | 2025 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $34.53 | 2023-2024 | Jornay Pm |
| Tris Pharma INC | $26.84 | 2025 | Dyanavel Xr |
| Janssen Biotech, INC. | $23.02 | 2023 | |
| Idorsia Pharmaceuticals US INC | $22.59 | 2022 | |
| Eisai INC. | $17.33 | 2022 | |
| Sage Therapeutics, LLC | $16.41 | 2025 | Zurzuvae |
| E.R. Squibb & Sons, L.L.C. | $15.88 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Hebert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.